Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Laco, Gary S ^a  

^a LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DOUBLE STRANDED DNA; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE INHIBITOR; DRUG DERIVATIVE; INTERCALATING AGENT; LIGAND;

ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVE SITE; IN VITRO STUDY; LIGAND BINDING; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PROTEIN DNA INTERACTION; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION;

CAMPTOTHECIN; DNA; DNA TOPOISOMERASES, TYPE I; HUMANS; INTERCALATING AGENTS; LIGANDS; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE I INHIBITORS;

EID: 80052279409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024314     Document Type: Article

References (29)

1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, et al. (1966) Plant antitumor agents. I. The isolation and structure of camptothecin. A novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. Journal of the American Chemical Society 88: 3888-3890.
2. Hsiang YH, Hertzberg R, Hecht S, Liu LF, (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878.
3. Nitiss J, Wang JC, (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A 85: 7501-7505.
4. Hertzberg RP, Caranfa MJ, Hecht SM, (1989) On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28: 4629-4638.
5. Hsiang YH, Lihou MG, Liu LF, (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082.
6. Bendixen C, Thomsen B, Alsner J, Westergaard O, (1990) Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 29: 5613-5619.
7. Li TK, Liu LF, (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41: 53-77.
8. Du W, (2003) Towards new anticancer drugs: A decade of advances in synthesis of camptothecins and related alkaloids. Tetrahedron 59: 8649-8687.
9. Teicher BA, (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75: 1262-1271.
10. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, et al. (1992) Reduced intracellular drug accumulation in the absence of p-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human mcf-7 breast cancer cells. Cancer Res 52: 6175-6181.
11. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG, (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279: 1504-1513.
12. Burgin AB Jr, Huizenga BN, Nash HA, (1995) A novel suicide substrate for DNA topoisomerases and site-specific recombinases. Nucleic Acids Res 23: 2973-2979.
13. Henningfeld KA, Arslan T, Hecht SM, (1996) Alteration of DNA primary structure by DNA topoisomerase I. Isolation of the covalent topoisomerase I-DNA binary complex in enzymatically competent form. J Am Chem Soc 118: 11701-11714.
14. Kerrigan JE, Pilch DS, (2001) A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin. Biochemistry 40: 9792-9798.
15. Laco GS, Du W, Kohlhagen G, Sayer JM, Jerina DM, et al. (2004) Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies. Bioorg Med Chem 12: 5225-5235.
16. Laco GS, Collins JR, Luke BT, Kroth K, Sayer JM, et al. (2002) Human topoisomerase I inhibition: Docking camptothecin and derivatives into a structure-based active site model. Biochemistry 41: 1428-1435.
17. Laco GS, Pommier Y, (2008) Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition. Biochem J 411: 523-530.
18. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, et al. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci 99: 15387-15392.
19. Staker BL, Feese MD, Cushman M, Pommier Y, Zembower D, et al. (2005) Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 48: 2336-2345.
20. Wang X, Zhou X, Hecht SM, (1999) Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. Biochemistry 38: 4374-4381.
21. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, et al. (1991) Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98-107.
22. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y, (1995) Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34: 7200-7206.
23. Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, et al. (2001) Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 61: 1964-1969.
24. Biffinger JC, Kim HW, DiMagno SG, (2004) The polar hydrophobicity of fluorinated compounds. Chembiochem 5: 622-627.
25. Street IP, Armstrong CR, Withers SG, (1986) Hydrogen bonding and specificity. Fluorodeoxy sugars as probes of hydrogen bonding in the glycogen phosphorylase-glucose complex. Biochemistry 25: 6021-6027.
26. Porter SE, Champoux JJ, (1989) Mapping in vivo topoisomerase I sites on simian virus 40 DNA: Asymmetric distribution of sites on replicating molecules. Mol Cell Biol 9: 541-550.
27. Mancini G, D'Annessa I, Coletta A, Sanna N, Chillemi G, et al. (2010) Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I- DNA complex. PLoS One 5: e10934.
28. Fersht AR, Shi JP, Knill-Jones J, Lowe DM, Wilkinson AJ, et al. (1985) Hydrogen bonding and biological specificity analyzed by protein engineering. Nature 314: 235-238.
29. Steiner T, (2002) The hydrogen bond in the solid state. Angew Chem Int Ed 41: 48-76.